Drugs / Carbocysteine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT04140214 | Jun 2018 → Sep 2024 | bronchiectasis | Belfast Health and Social Care Trust | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02015598 | Dec 2013 → May 2014 | obstructive sleep apnea syndrome | Guangzhou Institute of Respiratory Disease | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06863376 Comparator | Mar 2025 → Mar 2027 expected | NAFLD1 | Tanta University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Carbocysteine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02015598 ↗ |
| Route | Oral | “One group is treated with oral intake of Antioxidant Carbocysteine 500mg tid.” NCT02015598 ↗ |